Shuttle Pharmaceuticals Holdings, Inc. SHPH
Regular-session close
After hours · Nov 19, 4:00 PM ET
- YTD
- -78.33%
- 1 year
- -80.30%
5D -1.02 (-19.17%)
- Market cap
- 18.58M
- EPS (ttm)
- -16.87
- Shares out
- 3.66M
- YTD return
- -78.33%
- 1-year return
- -80.30%
- 50-day average
- 1.06
- 200-day average
- 2.42
- Volume
- 31.27K
- Avg volume
- 41.49K
- Open
- 3.70
- Previous close
- 3.82
- Day's range
- 3.40 – 3.90
- 52-week range
- 2.58 – 44.40
- Beta
- 0.74
Key statistics
- Enterprise value
- 1.20M
- Price / book
- 0.35
- Free cash flow
- -2.49M
- Total cash
- 2.34M
- Total debt
- 1.16M
- Return on equity
- -186.00%
- Short % of float
- 27.91%
Fundamental scorecard
4 of 25 checks passed on SHPH’s reported financials
4of 25 checks passed
- Value 1 of 5
- Growth 1 of 5
- Profitability 0 of 5
- Financial health 2 of 5
- Dividend 0 of 5
Statements to Jun 30, 2026.
Financials — quick view
About Shuttle Pharmaceuticals Holdings, Inc.
Shuttle Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers . The company is based in Gaithersburg, Maryland.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- United States
- Website
- shuttlepharma.com
News
No recent headlines
Headlines appear here as they are published.
Your note
Sign in to keep a note on SHPH — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ADKINS WILLIAM H | Founder | Sale | Dec 28, 2022 | 184,071 |
| BROWN MILTON | Director | Sale | Dec 12, 2023 | 1,094,610 |
| DRITSCHILO ANATOLY | Chief Executive Officer | Stock Gift | Aug 13, 2023 | 0 |
| DRITSCHILO PETER | President | Sale | Dec 28, 2022 | 6,560 |
| JACOBS BETTE | Director | Sale | Dec 12, 2023 | 27,064 |
| JUNG MIRA | Officer | Sale | Dec 28, 2022 | 1,071,390 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| HRT Financial LP | 0.71% | 25,866 | 18.49K | Sep 29, 2024 |
| Tower Research Capital LLC (TRC) | 0.11% | 3,858 | 2.76K | Sep 29, 2024 |
| Federation Des Caisses Desjardins Du Quebec | 0.00% | 63 | 45 | Sep 29, 2024 |
| Bank of America Corporation | 0.00% | 9 | 6 | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 0.09% | 3,151 | 2.25K | Oct 30, 2024 |
| Fidelity NASDAQ Composite Index Fund | 0.02% | 616 | 440 | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.01% | 501 | 358 | Oct 30, 2024 |
